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Abstract
Introduction Few markers are available that can predict
response to tamoxifen treatment in estrogen receptor (ER)-
positive breast cancers. Identification of such markers would be
clinically useful. We attempted to identify molecular markers
associated with tamoxifen failure in breast cancer.
Methods Eighteen initially ER-positive patients treated with
tamoxifen requiring salvage surgery (tamoxifen failure [TF]
patients) were compared with 17 patients who were disease
free 5 years after surgery plus tamoxifen adjuvant therapy
(control patients). cDNA microarray, real-time quantitative PCR,
and immunohistochemistry on tissue microarrays were used to
generate and confirm a gene signature associated with
tamoxifen failure. An independent series of 33 breast tumor
samples from patients who relapsed (n = 14) or did not relapse
(n = 19) under tamoxifen treatment from a different geographic
location was subsequently used to explore the gene expression
signature identified.
Results Using a screening set of 18 tumor samples (from eight
control patients and 10 TF patients), a 47-gene signature
discriminating between TF and control samples was identified
using cDNA arrays. In addition to ESR1/ERα, the top-ranked
genes selected by statistical cross-analyses were MET, FOS,
SNCG, IGFBP4, and BCL2, which were subsequently
validated in a larger set of tumor samples (from 17 control
patients and 18 TF patients). Confirmation at the protein level by
tissue microarray immunohistochemistry was observed for ER-
α, γ-synuclein, and insulin-like growth factor binding protein 4
proteins in the 35 original samples. In an independent series of
breast tumor samples (19 nonrelapsing and 14 relapsing),
reduced expression of ESR1/ERα, IGFBP4, SNCG, BCL2, and
FOS was observed in the relapsing group and was associated
with a shorter overall survival. Low mRNA expression levels of
ESR1/ERα, BCL2, and FOS were also associated with a
shorter relapse-free survival (RFS). Using a Cox multivariate
regression analysis, we identified BCL2 and FOS as
independent prognostic markers associated with RFS. Finally,
the BCL2/FOS signature was demonstrated to have more
accurate prognostic value for RFS than ESR1/ERα alone
(likelihood ratio test).
Conclusions We identified molecular markers including a
BCL2/FOS signature associated with tamoxifen failure; these
markers may have clinical potential in the management of ER-
positive breast cancer.Page 1 of 17
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CI: confidence interval; ER: estrogen receptor; HR: hazard ratio; IGFBP: insulin-like growth factor binding protein; OS: overall survival; PCR: polymer-
ase chain reaction; RFS: relapse-free survival; RTQ-PCR: real-time quantitative PCR; SNCG: γ-synuclein; TF: tamoxifen failure; TMA: tissue microar-
ray.
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Breast cancer remains a global public health problem, with
some 1.1 million women newly diagnosed with breast cancer
in 2002 [1]. Nevertheless, there has been a decline in breast
cancer mortality in the Western world over the past decade,
which is at least in part attributable to the use of tamoxifen
adjuvant therapy [2,3]. For estrogen receptor (ER)-positive
cancers, 5 years of adjuvant tamoxifen therapy reduces the
annual breast cancer death rate by 31%, with a persistent
cumulative effect even 15 years after primary treatment [3].
Impressive early data with tamoxifen in the adjuvant setting led
clinicians to use tamoxifen as neoadjuvant therapy to avoid
surgery in elderly women with ER-positive cancer [4]. How-
ever, long-term follow up and clinical trials demonstrated that
up to 62% of cancers initially responsive to endocrine therapy
subsequently escaped control, with the patient then requiring
salvage surgery [4,5]. Thus, the use of tamoxifen as primary
endocrine therapy has been reserved for patients who decline
or are unfit for surgery as first-line therapy.
Although aromatase inhibitors may replace tamoxifen as first-
line neoadjuvant and adjuvant endocrine therapy for most
postmenopausal women, tamoxifen will continue to play a role
in premenopausal women as a second-line therapy in post-
menopausal women and in chemoprevention for all age
groups [6]. However, the molecular mechanisms that are
involved in the chemoresistance to tamoxifen remain unclear;
understanding such processes could benefit clinical decision
making.
Recent advances in genomics have provided tools that allow
gene expression profiling of solid tumors. Various studies
examining gene expression profiles of breast cancer have
allowed the molecular classification of clinically distinct sub-
classes of tumors [7,8] and the identification of molecular
markers associated with prognosis/clinical outcome [9-11]
and of predictive signatures that relate to therapeutic
response [12,13]. In this study our aims was to identify a set
of candidate molecular markers associated with failure of
tamoxifen treatment and that can discriminate between
patients with tamoxifen-sensitive breast cancer and those with
tamoxifen-resistant breast cancer. These molecular markers
could be useful in a clinical setting to plan patient management
based on tumor biology. To achieve our objectives, we used a
variety of techniques: cDNA arrays to identify a discriminatory
gene expression signature, real-time quantitative PCR (RTQ-
PCR) to examine gene expression at the transcript level, and
tissue microarrays (TMAs) with immunohistochemistry to look
at protein expression levels of the candidate markers in a first
cohort of breast tumor samples. An independent cohort of
patients from a different geographical location was then used
to assess, using RTQ-PCR, the pertinence of the molecular
markers identified. This work presents a step toward using
molecular markers of tamoxifen failure as tools of clinical utility.
Materials and methods
Cohort of patients and breast tumor samples used for 
biomarker identification
A first cohort of 35 postmenopausal Caucasian women (age
range 41 to 92 years; median age 74 years) with ER-α-posi-
tive primary breast cancer diagnosed at the Ninewells Hospital
(Dundee, UK), for whom complete clinical and pathological
data were available, were studied (Table 1). Eighteen women
were considered initially unfit for surgery or declined surgical
intervention and received neoadjuvant tamoxifen therapy only
(20 mg/day). Tumors were monitored by clinical caliper meas-
urement and mammography. After an initial response, as indi-
cated by a clinical and mammographic reduction in tumor size,
the tumors increased in size despite tamoxifen therapy and
were removed by surgical excision (tamoxifen failure [TF]
group; n = 18) and used in the study. No tissue from these
patients prior to endocrine therapy was available. Breast tumor
samples from the control group (age-matched women
selected from the same geographic and ethnic population who
underwent surgical resection before any endocrine therapy,
and who did not exhibit any cancer recurrence for 5 years after
primary surgical resection and subsequent adjuvant treatment
with tamoxifen alone) were excised. Using the χ2 test, there
was no significant difference in age, histologic grade, lymph
node status, or tumor size between the two groups (Table 1).
Informed consent was obtained from all patients, and the study
was approved by the ethics committee of the institution.
From this cohort, 18 tumor samples (from eight control
patients and 10 TF patients), for which sufficient total RNA
could be obtained, were used in the initial cDNA array investi-
gation; the whole set (17 control samples and 18 TF samples)
was used for RTQ-PCR measurements; and 33 samples were
used to conduct the TMA experiments (16 control samples
and 17 TF samples; formalin-fixed paraffin-embedded blocks
were not available for two patients).
Total RNA extraction
Surgical resection specimens were transported fresh to the
adjacent pathology laboratory, and small pieces of tumor tis-
sue were dissected out by a pathologist and snap frozen in liq-
uid nitrogen before storage at -80°C. Approximately 10 mg
tissue was homogenized in 750 μl QIAzol lysis reagent (Qia-
gen Ltd, Crawley, West Sussex, UK). RNA quality was
assured using the BioAnalyzer 2100™ (Agilent Technologies,
Palo Alto, CA, USA).
Transcriptome study by cDNA-array technology
Eighteen tumor samples (from eight control patients and 10 TF
patients) were used in cDNA array analysis (screening set).
Gene expression levels were determined using large-scale
measurement experiments using customized nylon cDNA
arrays (7.5 × 11.5 cm; 1,034 human genes; 12 genes/cm2)
produced in our facility (TAGC Laboratory, University of Aix-
Marseille II, France), as previously described [14-16]. Follow-Page 2 of 17
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sized by reverse transcribing 5 μg total RNA [14],
hybridization signals were scanned with a FUJI BAS 5000
beta imager (Raytest, Asnieres, France) and then quantified
with the BZScan software, in accordance with the developers'
recommendations [17] (TAGC Laboratory, Marseille, France).
Intensity values were then adjusted using a normalization step
based on the DNA quantification of each spot and the sum of
intensities detected in each experiment.
We conducted supervised analyses of genes that could allow
discrimination between the two classes of tumor samples
(control and TF) by cross-analyzing the results given by three
independent methods: supervised analysis using a signal-to-
noise metric [18]; significance analysis of microarrays [19];
and Mann-Whitney test (P < 0.05). For each method, we con-
sidered the ranks assigned for each gene, and we selected the
genes with the best sum of the ranks obtained using the three
methods. Expression profiles were then analyzed by hierarchi-
cal clustering using the Cluster program developed by Eisen
and colleagues [20], and the results visualized using Treeview
software (Eisen Laboratory, Berkeley, CA, USA).
Real-time quantitative PCR analysis
Using RTQ-PCR, tumor samples were examined as previously
described [15], using a LightCycler® 1.5 (Roche, Meylan,
France) in combination with the LightCycler Faststart DNA
Master Sybr Green I (Roche), in accordance to the manufac-
turer's recommendations. For each gene, the amount of target
was calculated as follows by normalization to the expression of
the 28S gene and relative to the calibrator: E-(ΔCTsample-ΔCTcali-
brator), where E is the efficiency of the RTQ-PCR reaction cal-
culated with the slope of the corresponding standard curve,
CT is the threshold cycle, and ΔCT is (CT target gene – CT
28S). Statistical analysis of RTQ-PCR measurements was
performed using the Mann-Whitney test and the Spearman's
rank test, by Statgraphics® 3 plus software (Statgraphics Cen-
turion, Herndon, VA, USA). The results were judged to be sta-
tistically significant at a confidence level greater than 95% (P
<0.05).
Tissue microarray experiments
Thirty-three tumor samples (16 control and 17 TF) were used
to construct a TMA, containing up to six 0.6 mm diameter
cores from each invasive breast tumor using a manual tissue
arrayer (Beecher Instruments Inc., Sun Prairie, WI, USA).
Briefly, hemotoxylin and eosin stained tumor sections were
reviewed by a single pathologist (KER), and areas suitable for
inclusion in the TMA marked. Sections were matched to their
corresponding wax blocks (the donor blocks), and 0.6 mm
diameter cores of tumor were removed from these donor
blocks and inserted into the recipient paraffin TMA block in a
grid arrangement.
Four micrometer sections were cut from the TMA block and
placed onto poly-L-lysine coated glass slides (VWR Interna-
tional Ltd., Lutterworth, UK) and dried for 1 hour at 60°C,
before being de-paraffinized in Histoclear (National Diagnos-
tics, Hessle, UK) and rehydrated through a graded alcohol
series. Citric acid buffer (10 mmol/l, pH 6.0) was used as a
standard microwave-based antigen retrieval method. Sections
were microwaved in a microwave compatible pressure vessel
Table 1
Initial cohort of patients (Ninewells Hospital, Dundee, UK): characteristics of the 35 patients with initially ER-positive primary breast 
cancer
Characteristic Control group (n = 17) TF group (n = 18) Pa
Age (years)
<70 5 4 NS (0.92)
≥ 70 12 14
Histological gradeb
I + II 14 8 NS (0.11)
III 3 8
Lymph node status
Node negative 10 4 NS (0.06)
Node positive 7 14
Macroscopic tumor sizec
<30 mm 11 6 NS (0.17)
≥ 30 mm 6 11
aP-value (χ2 test) was considered significant when P < 0.05. bInformation available for 33 patients. cInformation available for 34 patients. ER, 
estrogen receptor; NS, not significant; TF, tamoxifen failure.Page 3 of 17
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stainer Universal Staining System (Dako, Ely, UK) using
Vectastain® ABC kits (Vector Labs, Peterborough, UK), in
accordance with the manufacturer's protocol. Briefly, sections
were blocked by either normal goat or horse serum containing
10% (vol/vol) from stock avidin solution (Vector Labs) for 20
minutes followed by incubation with primary antibody, includ-
ing 10% (vol/vol) from stock biotin solution (Vector Labs) for 1
hour to reduce nonspecific background staining. The following
anti-human antibodies were used as primary antibodies: anti-
insulin-like growth factor binding protein 4 (anti-IGFBP4;
ab4252); anti-c-Fos (ab7963); anti-γ-synuclein (anti-SNCG;
ab6169; Abcam Ltd, Cambridge, UK); anti-Bcl2 (clone 124;
Dako); anti-ER-α clone 6F11 (Vision BioSystems, Newcastle-
upon-Tyne, UK); and anti-c-Met (CVD13; Zymed® Laborato-
ries Inc., Paisley, UK). Sections were then incubated with
either biotinylated anti-rabbit or anti-mouse antibody for 30
minutes followed by Vectastain® Elite ABC reagent for another
30 minutes. Liquid diaminobenzidine (Dako) was used as a
chromogenic agent for 5 minutes and sections were counter-
stained with Mayer's hematoxylin. In between each immunos-
taining step, slides were washed briefly in Tris-buffered saline
(pH 7.6). Sections known to stain positively were included in
each batch, and negative controls were prepared by replacing
the primary antibody with Tris-buffered saline.
TMA scoring was carried out independently by one of the
authors (KER, SMH), and concordance was confirmed by a
specialist breast pathologist (CAP) using a Nikon Eclipse
E600 light microscope. Antibody staining of cores containing
tumor were assessed using a scoring system based on the
quickscore method [21]. Briefly, the proportion of positive
cells was estimated and given a score on a scale from 1 to 6
(1 = 0% to 4%; 2 = 5% to 19%; 3 = 20% to 39%; 4 = 40%
to 59%; 5 = 60% to 79%; and 6 = 80% to 100%). The aver-
age intensity of the positively staining cells was estimated and
given a score from 0 to 3 (0 = no staining; 1 = weak staining;
2 = intermediate staining; and 3 = strong staining). A quick-
score was then calculated by multiplying the percentage of
cells staining score by the intensity score, to yield a minimum
value of 0 and a maximum value of 18.
Independent cohort of breast tumor samples of 
tamoxifen failure
A separate cohort of 33 Caucasian women (age range 31 to
77 years; median age 55.5 years) with ER-positive primary
breast cancer diagnosed at Centre Léon Bérard (Lyon,
France) were selected (Table 2) and provided by the Centre
de Ressources Biologiques of the Centre Léon Bérard (Lyon,
France). The breast tumor samples were excised from women
who did not receive endocrine therapy, chemotherapy, or radi-
otherapy before surgery. Complete clinical, histologic, and
biologic information was available. All patients received post-
operative adjuvant endocrine therapy alone for 5 years
(tamoxifen 20 mg/day) and no chemotherapy. Fourteen
patients relapsed under tamoxifen treatment (relapsing group)
and 19 patients did not have a recurrence after 5 years of
tamoxifen treatment (nonrelapsing group). Informed consent
was obtained from all patients. Using the χ2 test, there were no
significant differences between groups in age, histologic
grade, lymph node status, or tumor size (Table 2).
RNA extraction was performed as described above. RTQ-
PCR experiments were conducted using a LightCycler 480®
Table 2
Independent cohort of patients used for validation (Centre Léon Bérard, Lyon, France): characteristics of the 33 patients with 
initially ER-positive primary breast cancer
Characteristic Control group (n = 19) TF group (n = 14) Pa
Age (years)
<70 16 8 NS (0.18)
≥ 70 3 6
Histological grade
I + II 12 8 NS (1)
III 7 6
Lymph node status
Node negative 0 0 NS (1)
Node positive 19 14
Macroscopic tumor size
<30 mm 10 9 NS (0.75)
≥ 30 mm 9 5
aP value (χ2 test) was considered significant when P < 0.05. ER, estrogen receptor; NS, not significant; TF, tamoxifen failure.Page 4 of 17
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Mix (Roche), in accordance with the manufacturer's recom-
mendations. The expression of the six genes was investigated
using the same pair of primers, and the same calculation and
normalization methods as described above. Statistical analysis
of RTQ-PCR measurements was performed using the Mann-
Whitney test using the Statgraphics® 3 plus software (Stat-
graphics Centurion). The results were judged statistically sig-
nificant at a confidence level greater than 95% (P <0.05).
For each gene, the 33 ER-positive breast tumors were then
divided into two groups: one of 16 tumors with 'low' mRNA
level (lower than the median of the mRNA levels of the 33
breast tumor samples) and another of 17 tumors with 'high'
mRNA level (higher than the median of the mRNA levels of the
33 breast tumor samples). Outcomes of interest were overall
survival (OS) and relapse-free survival (RFS). OS was meas-
ured from the date of diagnosis to death or censored at the
last follow up. RFS was measured from the date of diagnosis
to relapse or censored at the last follow-up. Survival distribu-
tions were estimated using the Kaplan-Meier method and the
significance of differences between survival rates was ascer-
tained by the log-rank test, using the SPSS® Software (SPSS
Inc., Chicago, IL, USA). Candidate prognostic factors for RFS
with a 0.05 significance level in univariate analysis were
entered in a multivariate Cox model, and a backward selection
procedure was used to build the final model [22]. Likelihood
ratio test was used to select the best fit between models [23].
General considerations in statistical analyses
Because this study is an exploratory analysis, all of the statisti-
cal analyses performed in this work were done at the 0.05 sig-
nificance level, and no correction was applied for multiple
testing.
Results
Identification of a discriminating 47-gene signature 
associated with tamoxifen failure
cDNA arrays were used to identify candidate genes associ-
ated with tamoxifen failure. From a training set of 18 tumor
samples (eight control and 10 TF), total RNA was extracted
from each sample and used to synthesize the corresponding
complex probe to be hybridized on the cDNA arrays. With the
aim being to identify a molecular signature that might allow dis-
crimination between the two classes of tumor samples (con-
trol and TF), a cross-analysis based on three different
statistical methods (significance analysis of microarrays, sig-
nal-to-noise statistic method, and Mann-Whitney test) was
applied to the normalized cDNA array data. For each method,
the ranks assigned to each gene were considered, and the
genes selected with the best sum of the ranks obtained using
the three methods. Forty-nine discriminant genes arose, and
hierarchical clustering of the gene expression profiles discrim-
inated between the two groups of patients (control and TF;
Figure 1). Two out of the 49 discriminating genes (HLA-DRA
and STAT1) were selected by two individual spots located at
different places on the array, emphasizing the reproducibility of
the gene signature identified.
Functional annotation of the 47 genes in the signature showed
that 34% of the genes were involved in immune response
(B2M, CCL2, CCL3, CD22, CD33, CXCL12, HLA-A, HLA-
DPB1, HLA-DRA, IL10RA, IL16, IL2RG, IL6, ILF2, TCRA,
and TNFRSF7), 23% in transcription regulation (ELF1, ESR1/
ERα, FOS, JUN, JUNB, MAZ, NFYA, PBX1, RXRA, STAT1,
and ZNF607), 23% in cellular proliferation regulation and
mitosis control (DLEU2, IGFBP4, MAP2K2, MET, NF1,
NOTCH4, PAK1, SNCG, SSSCA1, TEK, and TGFBR2), 9%
in tumor invasion (AMFR, FLT1, MMP13, and MMP16), 4% in
apoptosis (BCL2 and FAS), 4% in cell adhesion (CD34 and
RDX), and 3% in other functions. Sixteen genes encoded pro-
teins of the immune system: major histocompatibility complex
proteins (B2M, HLA-A, HLA-DPB1, HLA-DRA, and TCRA),
cell antigen (CD22 and CD33), receptors (IL2RG, IL10RA,
and TNFRSF7), cytokines and chemokines (IL6, IL16, CCL2,
CCL3, and CXCL12), and a transcription factor (ILF2). In
addition, three of the 23% of genes involved in transcription
regulation were genes that take part in the activator protein-1
transcription complex (FOS, JUN, and JUNB). Interestingly,
expression of 17 genes from the 47-gene signature selected
in our study (Figure 1 [red asterisks]) was associated with
estrogen action, because their expression was modulated by
estradiol treatment in breast cancer cells in vitro [15,24-31].
This suggests that identification of estradiol-regulated genes
[32] or tamoxifen-regulated genes [33] in vitro might be a
good approach to selecting prognostic or predictive molecular
markers of ER-positive breast cancer [32-34].
Real-time quantitative PCR investigation of the six top-
ranked genes: ESR1/ERα, MET, FOS, SNCG, IGFBP4, 
and BCL2
Considering the rank assigned to each gene following the sta-
tistical cross-analysis performed on the cDNA array data (as
described in the Materials and methods section [above]),
ESR1/ERα emerged as the most discriminating gene, as
expected [35-38]. We then investigated the expression of
ESR1/ERα and that of the five following top-ranked genes
(MET, FOS, SNCG, IGFBP4, and BCL2) by RTQ-PCR on the
initial set of 18 tumor samples (eight control and 10 TF). Using
Spearman rank correlation, for five genes (ESR1/ERα, FOS,
IGFBP4, MET, and SNCG) the data demonstrated a positive
and significant (P < 0.05) correlation between mRNA levels
measured by cDNA array and RTQ-PCR, indicating consist-
ency between the cDNA array and the RTQ-PCR measure-
ments (Table 3).
To explore the reliability of the expression signature previously
identified by cDNA array, RTQ-PCR of ESR1/ERα, FOS,
IGFBP4, MET, BCL2, and SNCG gene expression was exam-
ined in a larger set of 35 tumor samples (17 control and 18Page 5 of 17
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Figure 1
Dendogram of 18 tumor samples (eight control and 10 TF). Using the Cluster and Treeview software packages, the samples were ordered accord-
ing to their degree of similarity after hierarchical clustering of the expression profiles of the 49 selected genes. Each column represents a tumor sam-
ple and each row a single gene. Expression levels above the median are presented in red and expression levels below the median are presented in 
green. The control tumor samples are colored blue, and the TF tumor samples yellow. Red asterisks represented genes whose expression is regu-
lated by estradiol treatment in breast cancer cell lines [15,24-31]. C, control; TF, tamoxifen failure.
Available online http://breast-cancer-research.com/content/10/5/R88TF), including the 18 samples used in the initial screen. The
data presented in Table 4 demonstrate a significant difference
of expression between the control and TF groups for the six
genes (Mann-Whitney test). As expected, ESR1/ERα
emerged as the most significant gene (P < 10-6). mRNA levels
of four genes (IGFBP4, SNCG, BCL2, and FOS) were signif-
icantly lower in the TF groups, whereas MET mRNA levels
were significantly higher in the TF group.
Using the Mann-Whitney test, the expression of the six genes
was compared with clinical and pathological parameters Table
1). ESR1/ERα (P = 0.002) and BCL2 (P = 0.003) genes had
significantly higher expression in axillary node metastasis-neg-
ative patients (n = 14) than in node-positive patients (n = 21).
Moreover, gene expression levels of ESR1/ERα (P = 0.004),
BCL2 (P = 0.003), and FOS (P = 0.01) were significantly
lower in grade III (n = 11) than in grade I + II (n = 22) tumor
samples. Finally, MET mRNA levels were significantly
increased (P = 0.016) in tumor grade III samples compared
with grade I + II samples.
Immunohistochemical examination of ER-α, c-Fos, 
IGFBP4, c-Met, SNCG, and Bcl2 on tissue microarray
In order to explore, at the protein level, the expression varia-
tions of the six top-ranked genes and to ascertain whether
immunohistochemical detection of these proteins on tissue
sections could differentiate between the control and the TF
groups, immunohistochemistry was performed on TMAs con-
taining cores of tissue from 33 out of the 35 patients (16 con-
trol and 17 TF; Figure 2). For two samples (one control and
one TF), tumor sections were not available. A Spearman rank
correlation test between the TMA data and the RTQ-PCR
measurements revealed a significant and positive correlation
for ESR1/ER-α (P < 10-4), Bcl2 (P = 0.003), and IGFBP4 (P
= 0.05; data not shown). The association of protein immuno-
histochemical detection with the control or TF group was stud-
ied using the Fisher exact test (Table 5). There was a
significant statistical association between ER-α (P = 0.0004),
Table 3
Spearman rank correlation between the cDNA-array and the 
RTQ-PCR measurements
Spearman correlation
Gene ra Pb
ESR1 0.93 0.0003
FOS 0.89 0.0006
IGFBP4 0.86 0.0008
MET 0.82 0.003
SNCG 0.78 0.005
BCL2 0.38 NS (0.14)
aSpearman rank correlation coefficient. bP value (Spearman rank 
correlation test) was considered significant when P < 0.05. NS, not 
significant.
Table 4
Statistical comparison of the mRNA levels measured by RTQ-PCR between the control and TF groups of tumor samples (Ninewells 
Hospital, Dundee, UK)
Genes Tumor samples Number of samples mRNA levels (arbitrary units)
Median Range Pa
ESR1 Control 17 72.71 28.14 to 261.30 <10-6
TF 18 1.98 0.13 to 20.85
IGFBP4 Control 17 2.53 1.44 to 5.93 0.0004
TF 18 1.12 0.15 to 3.24
MET Control 17 0.48 0.15 to 2.46 0.009
TF 18 1.23 0.18 to 12.51
FOS Control 17 0.36 0.04 to 2.54 0.02
TF 18 0.15 0.02 to 1.46
SNCG Control 17 0.78 0.08 to 34.01 0.036
TF 18 0.31 0.05 to 4.39
BCL2 Control 17 2.87 0.08 to 7.14 0.04
TF 18 1.08 0.13 to 6.8
aP value (Mann-Whitney test) was considered significant when P < 0.05. TF, tamoxifen failure.Page 7 of 17
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ical staining with patient group (control or TF). No significant
association was observed for c-Fos, c-Met, and Bcl2 protein
detection (P > 0.05).
Real-time quantitative PCR investigation of ESR1/ERα, 
MET, FOS, SNCG, IGFBP4, and BCL2 in an independent 
cohort of breast tumor samples
We examined an independent cohort of ER-positive breast
cancer patients from a different geographic location (Centre
Léon Bérard, Lyon, France) to assess the pertinence of the
biomarkers identified in the study. The separate cohort (n =
33) included 14 patients who relapsed under tamoxifen treat-
ment (relapsing group) and 19 patients who did not relapse
after 5 years of tamoxifen treatment (nonrelapsing group). In
this cohort, low mRNA levels of FOS, BCL2, SNCG, and
IGFBP4 were significantly associated with tamoxifen failure (P
< 0.05, Mann-Whitney test; Table 6). MET was the only
biomarker that could not be confirmed.
Prognosis significance of the biomarkers identified
We then used univariate analysis (log-rank test) to study fur-
ther the prognostic value of the biomarkers identified. Apart
from (as expected) ESR1/ERα (P < 10-4), univariate analysis
revealed that low expression mRNA levels of FOS (P < 10-4),
BCL2 (P < 10-4), SNCG (P = 0.008), and IGFBP4 (P =
0.038) were significantly associated with shorter OS (Figure
3 and Table 7). Low expression mRNA levels of ESR1/ERα,
BCL2, and FOS were also significantly associated with
shorter RFS (P < 10-4; Figure 4 and Table 8), whereas low
expression of SNCG and IGFBP4 was close to statistical sig-
nificance (P = 0.078 and P = 0.083, respectively; Figure 4).
No significant association between MET mRNA level and OS
(P = 0.879) or RFS (P = 0.449) could be identified. In Cox
multivariate regression analysis of OS, only the prognostic sig-
nificance of ESR1/ERα (P = 0.032; hazard ratio [HR] = 0.17,
95% confidence interval [CI] = 0.03 to 0.86) and FOS (P =
0.049; HR = 0.22, 95% CI = 0.06 to 1.00) persisted (Table
7). Cox multivariate regression analysis of RFS revealed that
BCL2 (P < 10-4; HR = 0.10, 95% CI = 0.03 to 0.34) and FOS
(P = 0.038; HR = 0.15, 95% CI = 0.03 to 0.89) were inde-
pendent prognostic markers and that patients with low mRNA
levels of BCL2 or FOS were at greater risk for relapse (Table
8).
We then defined a two-gene signature based on BCL2 and
FOS mRNA expression levels. This signature was constructed
by selecting patients who expressed low mRNA levels of both
BCL2 and FOS (group A; n = 14) versus patients exhibiting
high expression levels of at least one of these two genes
(group B; n = 19). Among these 19 patients, concomitant high
levels of both BCL2 and FOS were detected in 15 samples.
Concerning the four patients with high expression levels of
either BCL2 or FOS, the Kaplan-Meier curve for RFS could be
superimposed over those of the patients having high levels of
both BCL2 and FOS. The resulting Kaplan-Meier curves for
RFS according to the BCL2/FOS signature are illustrated in
Figure 5 (univariate analysis, P < 10-4; HR = 0.014, 95% CI =
0.002 to 0.117).
Finally, we tested the BCL2/FOS signature with respect to
RFS to determine which final model is better. The model with
the BCL2/FOS signature was better fitting (likelihood =
90.35) than the model with ESR1/ERα alone (likelihood =
109.28; P < 10-4) or with only BCL2 (likelihood = 102.64; P
Table 5
Statistical comparison of protein expression measured by TMA 
between the control and TF groups of tumor samples (n = 33; 
Ninewells Hospital, Dundee, UK)
Proteins Quickscore Samples (n [%]) Pa
Control TF
ER-α 0 and <4 1 (6) 11 (65) 0.0004
From 4 to <8 4 (25) 4 (24)
From 8 to <12 5 (31) 2 (12)
From 12 to 18 6 (38) 0 (0)
SNCG 0 and <4 0 (0) 0 (0) 0.02
From 4 to <8 6 (38) 7 (41)
From 8 to <12 1 (6) 7 (41)
From 12 to 18 9 (56) 3 (18)
IGFBP4 0 and <4 5 (31) 8 (47) 0.03
From 4 to <8 4 (25) 5 (29)
From 8 to <12 1 (6) 4 (24)
From 12 to 18 6 (38) 0 (0)
c-Fos 0 and <4 1 (6) 0 (0) NS (0.08)
From 4 to <8 7 (44) 2 (12)
From 8 to <12 1 (6) 2 (12)
From 12 to 18 7 (44) 13 (76)
c-Met 0 and <4 1 (6) 0 (0) NS (0.29)
From 4 to <8 1 (6) 4 (24)
From 8 to <12 6 (38) 8 (47)
From 12 to 18 8 (50) 5 (29)
Bcl2 0 and <4 5 (31) 7 (41) NS (0.78)
From 4 to <8 4 (25) 2 (12)
From 8 to <12 1 (6) 2 (12)
From 12 to 18 6 (38) 6 (35)
aP value (Fisher exact test) was considered significant when P < 
0.05. ER, estrogen receptor; IGFBP, insulin-like growth factor 
binding protein; NS, not significant; SNCG, γ-synuclein; TF, 
tamoxifen failure; TMA, tissue microarray.Page 8 of 17
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Figure 2
Example cores of breast tumors from the TMA. Presented are example cores of breast tumors from the TMA showing immunohistochemical staining 
for (a, b) ER-α, (c, d) IGFBP4, (e, f) SNCG, (g, h) Bcl2, (i, j) c-Met, and (k, l) c-Fos. Panel a shows weak staining for ER-α, b strong positive staining 
for ER-α, c negative staining for IGFBP4, d strong staining for IGFBP4, e weak positive staining for SNCG, f strong positive staining for SNCG, g 
negative staining for Bcl2, h strong positive staining for Bcl2, i negative staining for c-Met, j strong positive staining for c-Met, k negative staining for 
c-Fos, and l strong positive staining for c-Fos. All images were taken at ×40 objective. ER, estrogen receptor; IGFBP, insulin-like growth factor bind-
ing protein; SNCG, γ-synuclein; TMA, tissue microarray.
Breast Cancer Research    Vol 10 No 5    Vendrell et al.= 0.0005) or FOS (likelihood = 114.47; P < 10-4), demon-
strating that our two-gene signature has a better prognostic
value than ESR1/ERα alone for RFS. We then tested the
model with both BCL2/FOS and ESR1/ERα and found that
the combination was better fitting (likelihood = 89.82) than the
model with ESR1/ERα alone (likelihood = 109.28; P < 10-4),
demonstrating that the BCL2/FOS signature could improve
the prognostic value of ESR1/ERα for RFS.
Discussion
ER immunohistochemistry is a widely available but imperfect
test for guiding likely clinical response to tamoxifen treatment.
Using clinical material from women with ER-positive breast
cancers treated with tamoxifen alone, this study sought bio-
logic markers associated with tamoxifen failure in breast can-
cer. Transcriptome data identified a specific 47-gene
signature associated with tamoxifen failure.
A key issue in gene expression profiling studies is the difficulty
in finding overlapped gene expression profiles in independent
Table 6
Statistical comparison of the mRNA levels measured by RTQ-PCR between the nonrelapsing and relapsing groups of tumor 
samples from the independent cohort (Centre Léon Bérard, Lyon, France)
Genes Tumor samples Number of samples mRNA levels (arbitrary units)
Median Range Pa
ESR1 Nonrelapsing 19 117.9 0.33 to 472.35 0.0001
Relapsing 14 2.55 0.03 to 51.75
IGFBP4 Nonrelapsing 19 97.52 0.02 to 12691.41 0.02
Relapsing 14 1.40 0.01 to 7282.33
MET Nonrelapsing 19 0.10 0.08 to 10.26 NS (0.33)
Relapsing 14 0.12 0.10 to 2.28
FOS Nonrelapsing 19 8.72 0.03 to 47.92 0.0001
Relapsing 14 0.28 0.01 to 1.46
SNCG Nonrelapsing 19 5.99 0.04 to 915.74 0.005
Relapsing 14 0.52 0.01 to 18.28
BCL2 Nonrelapsing 19 5.59 0.01 to 17.24 0.0004
Relapsing 14 0.12 0.01 to 8.57
aP value (Mann-Whitney test) was considered significant when P < 0.05. NS, not significant; RTQ-PCR, real-time quantitative PCR.
Table 7
Univariate and multivariate analysis of the six genes in relation to OS among the 33 breast cancer samples from the independent 
cohort (Centre Léon Bérard, Lyon, France)
Genes Univariate (n = 33) Multivariate (n = 33)
HR 95% CI Pa HR 95% CI Pa
ESR1 0.09 0.02 to 0.38 <10-4 0.17 0.03 to 0.86 0.032
FOS 0.12 0.03 to 0.42 <10-4 0.22 0.06 to 1.00 0.049
BCL2 0.07 0.01 to 0.31 <10-4 NS(2)b
SNCG 0.24 0.08 to 0.75 0.008 NS(3)
IGFBP4 0.34 0.12 to 0.98 0.038 NS(1)
MET 1.08 0.40 to 2.88 NS NDc ND ND
aP value was considered significant when P < 0.05. bNS(i), order in which the variable was deleted from the model. cND indicates 'not done'; 
multivariate analysis was done using the variables found to be significant in univariate analysis. CI, confidence interval; HR, hazard ratio; NS, not 
significant; OS, overall survival.Page 10 of 17
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technology to identify molecular markers of tamoxifen resist-
ance, we did not find any overlap between the 47-gene signa-
ture of tamoxifen resistance identified and the molecular
markers previously identified in the few studies available
[13,39-42]. Only one gene (FLT1) identified here was present
in the 70-gene prognostic signature selected by van't Veer
and colleagues [11]. These differences could be due to tech-
nical differences in the cDNA array platforms, to the methods
of analysis used in each study, or (most probably) to patient
inclusion criteria. Fan and colleagues [43] compared the pre-
dictions derived from five gene expression profiling studies,
and the resulting analysis suggested that even though there
was little gene overlap between the different studies, the out-
come predictions were similar and probably tracked the same
phenotype, illustrated by the same functional clusters.
Among the functional clusters identified in the present study,
34% of the selected genes encode proteins that are involved
in immune response, and most of these genes (88%) were
under-expressed in the TF group. In accordance with our find-
ings, three other gene expression profiling studies also identi-
fied low expression mRNA levels of 'immune response' genes
in tamoxifen-resistant tumor samples [13,41,42]. Such down-
regulations could allow tamoxifen-resistant cells to escape cell
death induced by the immune system (for example, cytotoxic T
lymphocytes or natural killers cells), or these observations may
be a consequence of a modification of the cellular microenvi-
ronment in the tamoxifen-resistant tumor samples. However,
the dispersal of neoplastic and lymphocyte cells among stro-
mal tissues make this difficult to assess by cDNA array or
RTQ-PCR techniques (even with microdissection), but they
may be more amenable to the immunohistochemistry
approach.
Apart from the 'immune response' cluster, the 'proliferation'
cluster is frequently represented in gene expression signa-
tures associated with poor prognosis in breast cancer
[15,44,45] or in tamoxifen-treated breast cancer [40,42]. In
the present study, 23% of our 47-gene expression signature
also belonged to the proliferation cluster and included
IGFBP4, MET, and SNCG.
Many investigators have also considered the expression of
estrogen-regulated or estrogen-associated genes, because
they could provide valuable prognostic or predictive markers
of ER-positive breast cancers [32,33,39,45]. In the gene sig-
natures previously identified in tamoxifen-resistant breast car-
cinoma, 23% to 50% of the genes had been related to
estrogens, either as ER targets or ER regulators [13,40,42]. In
the present study, 36% of our 47-gene expression signature
associated with tamoxifen failure was related to estrogen
action, possibly indicating deregulation of the estrogen signal-
ing pathway. Finally, when compared to the chromosomal dis-
tribution of all the genes present on the cDNA arrays used in
this study, the chromosomal distribution of the 47 selected
genes exhibited a significant (P < 0.05) over-representation of
genes located on chromosomes 6, 11, 17, and 19 (data not
shown). Of the 47 genes, 43% were found to be localized to
six specific cytobands (6p21, 11q13, 11q23, 17q11-q21,
19p13, and 19q13). Genetic events located on specific cyto-
bands have previously been identified as associated with
tamoxifen resistance [13,41,46], and markers for high-level
amplification and/or deregulation of expression of genes at
11q13 and 17q12 were strong predictors of reduced survival
in breast cancer [47]. Taken together, these observations sug-
gest that deregulation of expression could be associated with
genetic alterations that may occur at specific chromosomal
loci in the development of tamoxifen resistance.
Based on the results obtained from the cross-analysis of three
different statistical analyses performed on the cDNA array
data, ESR1/ERα emerged as the premier gene, in accordance
with its well established prognostic and predictive value for
Table 8
Univariate and multivariate analysis of the six genes in relation to RFS among the 33 breast cancer samples from the independent 
cohort (Centre Léon Bérard, Lyon, France)
Genes Univariate (n = 33) Multivariate (n = 33)
HR 95% CI Pa HR 95% CI Pa
ESR1 0.12 0.04 to 0.36 <10-4 NS
FOS 0.20 0.08 to 0.51 <10-4 0.15 0.03 to 0.89 0.038
BCL2 0.08 0.02 to 0.24 <10-4 0.10 0.03 to 0.34 <10-4
SNCG 0.46 0.19 to 1.11 NS NDb ND ND
IGFBP4 0.46 0.19 to 1.12 NS ND ND ND
MET 1.38 0.60 to 3.21 NS ND ND ND
aP value was considered significant when P < 0.05. bND indicates 'not done'; multivariate analysis was done using the variables found to be 
significant in univariate analysis. CI, confidence interval; HR, hazard ratio; NS, not significant; RFS, relapse-free survival.Page 11 of 17
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Figure 3
Overall survival. Presented are Kaplan-Meier curves (log-rank test analysis) of breast cancer samples from the Centre Léon Bérard cohort. Effect of 
(a) ESR1/ERα, (b) FOS, (c) BCL2, (d) SNCG, (e) IGFBP4, and (f) MET mRNA levels on overall survival among the 33 breast cancer samples.
Available online http://breast-cancer-research.com/content/10/5/R88
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Figure 4
Relapse-free survival. Presented are Kaplan-Meier curves (log-rank test analysis) of breast cancer samples from the Centre Léon Bérard cohort. 
Effect of (a) ESR1/ERα, (b) FOS, (c) BCL2, (d) SNCG, (e) IGFBP4, and (f) MET mRNA levels on relapse-free survival among the 33 breast can-
cer samples.
Breast Cancer Research    Vol 10 No 5    Vendrell et al.endocrine therapy in breast cancer [35-38], and reinforced the
gene signature identified in this study. Among the five follow-
ing top-ranked genes (MET, FOS, SNCG, IGFBP4, and
BCL2), all were validated by RTQ-PCR experiments. How-
ever, only two (IGFBP4 and SNCG) of these five genes were
confirmed at the protein level using immunohistochemistry,
suggesting first (as observed by others) that the mRNA levels
are not always correlated with protein levels, and second that
the prognostic/predictive value of a given biomarker can differ
with the molecular level investigated (mRNA or protein)
[48,49]. In an independent cohort used to assess the perti-
nence of the biomarkers identified, low mRNAs levels of
ESR1/ERα but also of FOS, BCL2, SNCG, and IGFBP4
were significantly associated with tamoxifen failure. The data
obtained with the second cohort added new information, indi-
cating that gene expression differences may be inherent to a
primary breast tumor before endocrine therapy and might not
only reflect deregulation of expression induced by tamoxifen
exposure.
Among the six top-ranked genes, this study allowed identifica-
tion of reduced expression of FOS associated with tamoxifen
failure. Interestingly, in our cDNA array experiments, two other
members of the activator protein-1 complex, namely JUN and
JUNB, were also expressed to lesser degrees in tamoxifen-
resistant tumors than in control tumors. MET over-expression
may be linked to poor clinical outcome in patients with breast
cancer [50,51]. High BCL2 tumor expression was associated
with better outcome in endocrine-treated breast cancers [52-
56]. High levels of SNCG (also called BCSG1 [breast cancer-
specific gene 1]) have been identified in advanced breast car-
cinomas [57,58] and associated with poor clinical outcome
[59]. Recently reported data also demonstrated the role
played by SNCG as an ER chaperone and modulator of ER
signaling, suggesting that SNCG strongly contributes to the
tumorigenesis of ER-positive breast cancer [60], providing evi-
dence for crosstalk between SNCG and ER signaling.
IGFBP4 is a member of the IGFBP proteins and appears to be
a potent inhibitor of insulin-like growth factor function in sev-
eral cell lines [61-63]. IGFBP4, an estrogen-regulated gene
[15,64], is downregulated in tamoxifen-resistant cell lines [65],
forms part of a molecular signature of poor prognosis ER-pos-
itive breast cancer [32], and could help to identify people who
may benefit from endocrine therapy in ovarian cancer [66]. A
recent study also revealed that IGFBP4 mRNA expression is
an independent prognostic factor in breast cancer, and that
patients with ER-positive breast cancer with higher levels of
IGFBP4 tumor mRNA expression and lower levels of IGFBP5
mRNA had a better prognosis [67]. However, the number of
patients treated with endocrine therapy in that study was too
limited to evaluate the predictive value of IGFBP4 for endo-
crine therapy responsiveness.
When assessing the prognostic significance of the markers
identified, our analysis revealed several marker dependencies
and interactions. For example, although ESR1/ERα, FOS, and
BCL2 were significant univariate factors for RFS, only FOS
and BCL2 emerged as independent prognostic factors in mul-
tivariate analysis. In a previous study, reduced FOS gene
expression levels were associated with high histologic grade
in breast tumors [68]. However, to our knowledge, no study
has described any prognostic or predictive value of FOS in
endocrine-treated patients. A previous immunohistochemistry
study suggested that Bcl2 is an independent predictor of
breast cancer outcome [69]. In tamoxifen-treated ER-positive
patients, low Bcl2 protein expression levels are associated
with worse outcome [52-56], and independent prognostic
value of Bcl2 protein alone was observed in two studies
[54,56]. BCL2 and FOS are known to be estrogen-regulated
genes [15,33,70,71], and we observed in our study a signifi-
cant positive correlation (Spearman rank correlation test)
between ESR1/ERα mRNA levels and BCL2 (P < 0.0002) or
FOS (P < 0.01) mRNA levels, both in the first and second
cohort of patients (data not shown). Thus, high BCL2 levels
and/or high FOS levels may only reflect aggressiveness of the
disease or may be indicative of an intact pathway that is driving
tumor growth and that should be sensitive to endocrine ther-
apy. This raises the issue of whether the prognostic value for
RFS of the BCL2/FOS signature is more accurate than ESR1/
ERα mRNA levels. In this study, statistical analysis clearly
demonstrated that BCL2 alone was more informative than
ESR1/ERα mRNA levels, and that combination of BCL2 with
Figure 5
Effect of BCL2/FOS signature on relapse-free survival. Shown is the 
effect of the BCL2/FOS signature on relapse-free survival (Kaplan-
Meier curves, log-rank test analysis) among the Centre Léon Bérard 
cohort. Group A (n = 14) contains the breast cancer samples express-
ing low mRNA levels of both BCL2 and FOS. Group B (n = 19) is com-
posed of the breast cancer samples with high expression levels of at 
least one of these two genes.Page 14 of 17
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of BCL2. These data suggest that the biomarkers identified in
this study may represent candidate markers that could help in
stratifying ER-positive patients, facilitating selection of ther-
apy.
Conclusions
In this study we identified a gene expression signature and
molecular markers associated with tamoxifen failure in breast
cancer. RTQ-PCR may provide the best quantitative measure
of IGFBP4, BCL2, FOS, SNCG, and MET, particularly
because this technology is in common use in clinical laborato-
ries and could be applied to fine needle aspiration biopsy sam-
ples taken sequentially during treatment. Validation at the
protein level of SNCG and IGFBP4 using TMAs demonstrated
that immunohistochemistry of these proteins may be pursued
in the future as a therapeutic decision making tool. Moreover,
molecular markers encoding secreted proteins such as
IGFBP4, which was validated in this study both by RTQ-PCR
and immunohistochemistry, are interesting because they may
be investigated in the future in patient serum and offer thera-
peutic potential. Finally, the low expression levels of ESR1/
ERα, FOS, BCL2, SNCG, and IGFBP4 were found to be
associated with poor prognosis in an independent cohort of
patients exhibiting tamoxifen failure. We also demonstrated
the strong prognostic value of the BCL2/FOS signature in ER-
positive patients who relapsed under tamoxifen treatment.
To conclude, the present exploratory study identified new
biomarkers of tamoxifen failure that could be helpful in clinical
decision making in patients with endocrine-dependant breast
cancer. Because the biomarkers identified in this study were
confirmed in two independent patient groups, differences
between the two cohorts from different geographic location
(Ninewells Hospital and Centre Léon Bérard) is unlikely to
have influenced the gene signature. However, further work is
needed to evaluate the prognostic and/or predictive value of
these biomarkers in prospective studies using larger cohorts
of patients.
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